News | March 19, 2024
Dr. Reddy's Laboratories launches Versavo in the UK
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
Acquisition enhances Freenome's product portfolio, including autoantibody platform with additional biomarkers important in cancer detection
NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China
Launch of the Da Vinci Xi Robotic System is the highlight of the Robotic Colorectal Cancer Symposium organized with the Association of Colon and Rectal Surgeons of India
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
Twelve hospitals across India will be part of the network which will support the trial in India
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated colorectal cancer.
Subscribe To Our Newsletter & Stay Updated
